EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Innovent Biologics's Enterprise Value is HK$50,267 Mil.
Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-1,144 Mil. Therefore, Innovent Biologics's EV-to-EBIT for today is -43.94.
The historical rank and industry rank for Innovent Biologics's EV-to-EBIT or its related term are showing as below:
HKSE:01801'
s EV-to-EBIT Range Over the Past 10 Years
Min: -135.6 Med: -20.8 Max: -0.35
Current: -43.94
During the past 8 years, the highest EV-to-EBIT of Innovent Biologics was -0.35. The lowest was -135.60. And the median was -20.80.
HKSE:01801's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs HKSE:01801: -43.94
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Innovent Biologics's Enterprise Value for the quarter that ended in Jun. 2023 was HK$41,013 Mil.
Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-1,144 Mil. Innovent Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -2.79%.
Innovent Biologics EV-to-EBIT Historical Data
The historical data trend for Innovent Biologics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's EV-to-EBIT
For the Biotechnology subindustry, Innovent Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's EV-to-EBIT falls into.
Innovent Biologics EV-to-EBIT Calculation
Innovent Biologics's EV-to-EBIT for today is calculated as:
Innovent Biologics's current Enterprise Value is HK$50,267 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-1,144 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Innovent Biologics's Enterprise Value for the quarter that ended in Jun. 2023 was HK$41,013 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-1,144 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (HKSE:01801) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 